WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
Sponsors
U.S. Army Medical Research and Development Command
Conditions
Leishmaniasis, Cutaneous
Phase 2
Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
CompletedNCT01032382
Start: 2010-01-31End: 2011-07-31Updated: 2015-07-16
Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
CompletedNCT01083576
Start: 2010-03-31End: 2011-07-31Updated: 2015-07-16